An observational study in Tuberculous Meningitis, sponsored by Ina-Respond. Recruiting at 6 sites in Indonesia. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Ina-Respond · Observational
TBM Study is a multicenter, observational, retrospective cohort study of Tuberculous Meningitis (TBM) patients who underwent treatment at the hospital during the 2022-2025 period. The goal of this study is to learn about the clinical characteristics, diagnostic findings, drug resistance profiles, treatment regimens, complications, and treatment outcomes of patients diagnosed with TBM who were admitted to the study hospitals between 2022 and 2025. This study uses retrospective data obtained from electronic medical records (EMR).
Participants who admitted to the participating hospital sites between January 1, 2022, and December 31, 2025, have a discharge diagnosis of TBM (ICD-10 code A17.0) or documented TBM diagnosis in the hospital EMR system, and have accessible data available in the EMR will be enrolled to this study. The data will be collected at five timepoints:
Timepoint 1: Hospital Admission Timepoint 2: TB Treatment Initiation Timepoint 3: Hospital Discharge Timepoint 4: End of Intensive Phase Timepoint 5: End of Treatment
Six hospitals participate as the study sites. They are:
No biological specimens will be collected as part of the study. Data will be extracted from electronic medical records (EMR) at the study participating hospitals. Patient data will be collected from existing records at predefined time points through the end of treatment.
31 studies on the registry are indexed under Tuberculosis, Meningeal; 9 are open to participants now.
Browse Tuberculosis, Meningeal studies →Ina-Respond is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
The population of this study consists of patients diagnosed with TBM who were admitted to participating hospital sites. Eligible cases will be identified through hospital EMR systems using the ICD-10 code A17.0 or based on a documented diagnosis of TBM in the EMR and will be verified by clinical documentation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
None
No intervention (observational study)
The proportion of TBM cases across TBM categories of clinical characteristics, diagnostic findings, drug resistance profiles, treatment regimens, complications, and treatment outcomes according to the Marais consensus diagnostic criteria
Time frame: During TB treatment, an average 8-12 months
To estimate the annual trend of TBM admissions at the hospitals from 2022 to 2025
Time frame: at hospital admission timepoint
The proportion of TBM cases across comorbidities, concurrent pulmonary or extrapulmonary tuberculosis, and co-infections according to the Marais consensus diagnostic criteria
Time frame: During hospitalization, an average 2 weeks
The proportion of TBM cases across use and diagnostic yield of laboratory investigations and neuroimaging modalities according to the Marais consensus diagnostic criteria
Time frame: During TB treatment, an average 8-12 months
The proportion of TBM cases across factors associated with in-hospital mortality, end-of treatment outcome, and neurological sequelae according to the Marais consensus diagnostic criteria
Time frame: During TB treatment, an average 8-12 months
The proportion of TBM cases across post-discharge follow-up status and final treatment outcomes, including treatment completion, death, loss to follow-up (LTFU), and presence of neurological sequelae according to the Marais consensus diagnostic criteria
Time frame: During TB treatment, an average 8-12 months
The proportion of TBM disease severity, treatment, and outcomes, based on age group, HIV status, drug resistance status
Time frame: During TB treatment, an average 8-12 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ina-Respond